Patients taking selegiline may have received more levodopa than necessary

BMJ

Volumn 312, Issue 7032, 1996, Pages 702-703

  Olanow, C Warren ^a   Koller, William ^a   Godbold, James H ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; SELEGILINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MORTALITY; NOTE; PARKINSON DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; LEVODOPA; PARKINSON DISEASE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SELEGILINE;

EID: 85007772141     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7032.702b     Document Type: Letter

References (5)

1. Lees AJ on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602–7. (16 December.)
2. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. A longitudinal double blind controlled study of the affect of deprenyl and levodopa on the progression of the signs and symptoms of Parkinson's disease. Ann Neurol 1995; 38: 771–777.
3. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential trials. Control Clin Trials 1984; 5: 348–361.
4. Brannan T, Prikhojan A, Martinez-Tica J, Yahr MD. In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-dopa and dopamine metabolism. J Neural Transm (in press).
5. Przuntek H, Welzel D, Blumner E, Danielcyk W, Letzel H, Kaiser HJ, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: Prado study discontinued. Eur J Clin Pharmacol 1992; 43: 357–363.